| Domain | Key points | Best supporting sources | Publication info (year, journal) | URL |
|---|---|---|---|---|
| Identifiers/Definition | Testicular seminoma is a major histologic subtype of testicular germ cell tumors (TGCTs); TGCTs are divided into seminoma and nonseminomatous germ cell tumors. Seminoma comprises a little over half of testicular germ cell neoplasms, and pure seminoma accounts for ~40–50% of TGCTs in men aged 25–55. Seminoma is GCNIS-derived and typically has normal AFP, with possible β-hCG elevation in a subset. (pqac-00000001, pqac-00000006) | Fazekas 2024; Sykes et al. 2024 (pqac-00000001, pqac-00000006) | 2024, ArXiv; 2024, Journal of Clinical Medicine | https://doi.org/10.14232/phd.12359; https://doi.org/10.3390/jcm13237448 |
| Epidemiology | TGCTs most commonly affect men aged 20–39; U.S. incidence reported as 5.7/100,000 with an estimated 9,760 new U.S. cases in 2024. Seminoma peaks at age 35–39. Nearly 80% of seminoma patients present with clinical stage I disease. Long-term survival approaches ~99% for early-stage disease and >80% for advanced-stage disease. (pqac-00000001, pqac-00000003, pqac-00000006) | Fazekas 2024; Sykes et al. 2024 (pqac-00000001, pqac-00000003, pqac-00000006) | 2024, ArXiv; 2024, Journal of Clinical Medicine | https://doi.org/10.14232/phd.12359; https://doi.org/10.3390/jcm13237448 |
| Etiology/Risk | TGCTs arise from GCNIS/gonocyte precursor cells that remain senescent until puberty and then progress under hormonal and genetic influences; microenvironment interaction is implicated. Cryptorchidism is a strong risk factor: a 2024 review cites a meta-analysis estimating a fourfold increased testicular cancer risk in boys with congenital cryptorchidism. Maternal smoking in pregnancy was not associated with higher testicular cancer risk overall in meta-analysis and showed a lower, non-significant seminoma estimate (RR 0.79, 95% CI 0.59–1.04). Male infertility is also a risk factor in contemporary review literature. (pqac-00000008) | Cabral et al. 2023; supporting recent risk reviews/search results summarized in retrieved evidence (pqac-00000008) | 2023, Frontiers in Oncology | https://doi.org/10.3389/fonc.2023.1133363 |
| Molecular/Pathophysiology | Whole-genome sequencing identified recurrent chromosome arm-level gains spanning KRAS on 12p, consistent with 12p gain/i(12p)-type biology, and focal KIT amplifications (~19% of cases). Seminoma-relevant mutations/alterations across TGCT datasets include KIT, KRAS, NRAS, and PIK3CA; KRAS copy number gain was very frequent in one TGCT cohort (80.4%) and associated with worse 10-year OS (90% vs 81.5%, p=0.048). WGS also provided evidence that HLA loss is a more prevalent immune-disruption mechanism in seminomas. (pqac-00000008, pqac-00000009, pqac-00000000) | Cabral et al. 2023; Leathlobhair et al. 2024; Open Targets disease-target association context (pqac-00000008, pqac-00000009, pqac-00000000) | 2023, Frontiers in Oncology; 2024, Nature Communications | https://doi.org/10.3389/fonc.2023.1133363; https://doi.org/10.1038/s41467-024-53193-6 |
| Immune microenvironment | Seminoma histology is typically infiltrated by T lymphocytes and macrophages/dendritic cells. Recent profiling shows a shift from macrophage-dominant normal testis to T-cell-, B-cell-, and dendritic-cell-rich TGCT microenvironments. CD4+ T cells exceeded CD8+ in 96% of samples; densities decreased from tumor center to periphery. Rare Treg and Tfh subsets were identified and were most abundant in seminoma relative to mixed tumors and embryonal carcinoma. Single-cell/spatial multi-omics identified 15 immune cell subtypes and localized exhaustion-featured subtypes closer to tumor regions. (pqac-00000001, pqac-00000011) | Fazekas 2024; Islam et al. 2024; Lu et al. 2023 as summarized in gathered evidence (pqac-00000001, pqac-00000011) | 2024, ArXiv; 2024, British Journal of Cancer | https://doi.org/10.14232/phd.12359; https://doi.org/10.1038/s41416-024-02669-9 |
| Diagnostics/biomarkers | Conventional serum tumor markers are weak in pure seminoma: AFP is not elevated; β-hCG is mildly elevated in ~10–20% of pure seminoma and ~15–20% in advanced disease; LDH is elevated in ~40–60%. Reported seminoma sensitivities were AFP 2.3%, β-hCG 31%, LDH 28%, and 46% combined. miR-371a-3p is the leading emerging biomarker: reported overall sensitivity ~90–92% and specificity ~84–86% for TGCTs; in surveillance of stage I TGCT, relapse detection showed AUC 0.993, sensitivity 100%, specificity 96.3%, PPV 83%, NPV 100%; in prechemotherapy primary seminoma undergoing RPLND, sensitivity was 74% and specificity 100%. PET-CT has high negative predictive value for post-chemotherapy seminoma residual masses >3 cm but low positive predictive value because of false positives. (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000006, pqac-00000010, pqac-00000012) | Sykes et al. 2024; Thor et al. 2024; Belge et al. 2024; Fazekas 2024 (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000006, pqac-00000010, pqac-00000012) | 2024, Journal of Clinical Medicine; 2024, Journal of Urology; 2024, Clinical Cancer Research; 2024, ArXiv | https://doi.org/10.3390/jcm13237448; https://doi.org/10.1097/ju.0000000000004164; https://doi.org/10.1158/1078-0432.ccr-23-0730; https://doi.org/10.14232/phd.12359 |
| Treatment/outcomes | Radical inguinal orchiectomy is the main diagnostic and therapeutic procedure for localized seminoma. Surveillance is preferred for stage I because ~80–85% will not relapse after orchiectomy alone; recurrence risk is generally 15–20%, often within the first year. Alternative adjuvant options are single-agent carboplatin (1–2 cycles) or radiotherapy. A retrospective surveillance cohort reported 5-year survival of 99%. Seminoma is highly sensitive to radiotherapy and platinum chemotherapy; for stage IIA/IIB, RT or 3 cycles BEP / 4 cycles EP are established. Long-term toxicity is important, including cardiac toxicity, secondary malignancies, and an 80% increased risk of death from secondary malignancy associated with radiation in cited review evidence. (pqac-00000001, pqac-00000004) | Fazekas 2024; Sykes et al. 2024; Passarelli et al. 2024 identified in search results (pqac-00000001, pqac-00000004) | 2024, ArXiv; 2024, Journal of Clinical Medicine | https://doi.org/10.14232/phd.12359; https://doi.org/10.3390/jcm13237448 |
| Trials | Current biomarker implementation studies include a listed miR-371 trial for seminoma and NSGCT across stages (trial size note 350 in review evidence) and the SWENOTECA-MIR prospective multicenter study evaluating miR-371a-3p around RPLND. A recruiting observational study is registered as “A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors” (NCT07453082; enrollment 100). (pqac-00000005, pqac-00000010, pqac-00000012) | Sykes et al. 2024; Thor et al. 2024; ClinicalTrials retrieval context (pqac-00000005, pqac-00000010, pqac-00000012) | 2024, Journal of Clinical Medicine; 2024, Journal of Urology; ClinicalTrials.gov record | https://doi.org/10.3390/jcm13237448; https://doi.org/10.1097/ju.0000000000004164 |


*Table: This table condenses the strongest evidence gathered on testicular seminoma across definition, epidemiology, biology, diagnostics, treatment, and active trials. It is designed as a quick-reference artifact using only facts supported by the cited context IDs.*